Cargando…

Utility of a simplified [(18)F] sodium fluoride PET imaging method to quantify bone metabolic flux for a wide range of clinical applications

We review the rationale, methodology, and clinical utility of quantitative [(18)F] sodium fluoride ([(18)F]NaF) positron emission tomography-computed tomography (PET-CT) imaging to measure bone metabolic flux (K(i), also known as bone plasma clearance), a measurement indicative of the local rate of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puri, Tanuj, Frost, Michelle L., Moore, Amelia E. B., Choudhury, Ananya, Vinjamuri, Sobhan, Mahajan, Abhishek, Fynbo, Claire, Vrist, Marie, Theil, Jørn, Kairemo, Kalevi, Wong, James, Zaidi, Habib, Revheim, Mona-Elisabeth, Werner, Thomas J., Alavi, Abass, Cook, Gary J. R., Blake, Glen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534005/ https://www.ncbi.nlm.nih.gov/pubmed/37780613 http://dx.doi.org/10.3389/fendo.2023.1236881

Ejemplares similares

Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT
por: Kairemo, Kalevi, et al.
Publicado: (2015)

[(18)F] Sodium Fluoride PET Kinetic Parameters in Bone Imaging
por: Puri, Tanuj, et al.
Publicado: (2021)

Comparison of [18F] NaF PET/CT dynamic analysis methods and a static analysis method including derivation of a semi-population input function for site-specific measurements of bone formation in a population with chronic kidney disease-mineral and bone disorder
por: Vrist, M. H., et al.
Publicado: (2021)

Is interim (18)F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?
por: Etchebehere, Elba, et al.
Publicado: (2019)

A Short Dynamic Scan Method of Measuring Bone Metabolic Flux Using [(18)F]NaF PET
por: Puri, Tanuj, et al.
Publicado: (2021)

A Retrospective Comparative Study of Sodium Fluoride (NaF-18)-PET/CT and Fluorocholine (F-18-CH) PET/CT in the Evaluation of Skeletal Metastases in Metastatic Prostate Cancer Using a Volumetric 3-D Radiomics Analysis
por: Kairemo, Kalevi, et al.
Publicado: (2020)

Nuclear Medicine in Finland
por: Kairemo, Kalevi
Publicado: (2012)

A Retrospective Comparative Study of Sodium Fluoride Na(18)F-PET/CT and (68)Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic Analysis
por: Kairemo, Kalevi, et al.
Publicado: (2022)

Imaging of Accidental Contamination by Fluorine-18 Solution: A Quick Troubleshooting Procedure
por: Kairemo, Kalevi, et al.
Publicado: (2016)

Androgen Receptor Imaging in the Management of Hormone-Dependent Cancers with Emphasis on Prostate Cancer
por: Kairemo, Kalevi, et al.
Publicado: (2023)

Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
por: Kairemo, Kalevi, et al.
Publicado: (2019)

Incidental Detection of Asymptomatic Brain Metastases on (18)F-fluoride Positron Emission Tomography/Computed Tomography and (68)Ga DOTANOC Positron Emission Tomography/Computed Tomography in a Patient with Concomitant Breast Carcinoma and a Pancreatic Neuroendocrine Tumor
por: Brown, Ruth, et al.
Publicado: (2018)

Re: Aducanumab-Related ARIA: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

Alzheimer’s Disease at a Crossroad: Time to Part from Amyloid to More Promising Aspects—Atherosclerosis for a Start
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

The value of FDG-PET/CT imaging in the assessment, monitoring, and management of COVID-19
por: Griffin, Matthew T., et al.
Publicado: (2023)

Atherosclerosis imaging with (18)F-sodium fluoride PET: state-of-the-art review
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2019)

Comparison of I-131 Biokinetics after Recombinant Human TSH Stimulation and Thyroid Hormone Withdrawal Measured by External Detector in Patients with Differentiated Thyroid Cancer
por: Kairemo, Kalevi, et al.
Publicado: (2019)

Can Target-to-Background Ratio Measurement Lead to Detection and Accurate Quantification of Atherosclerosis With FDG PET? Likely Not
por: Alavi, Abass, et al.
Publicado: (2022)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

Communication of radiation risk in nuclear medicine: Are we saying the right thing?
por: Pandit, Manish, et al.
Publicado: (2014)

Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

123-Iodine MIBG in the Assessment of Sympathetic Denervation in Ogilvie's Syndrome
por: Bhoil, Amit, et al.
Publicado: (2022)

Preliminary Clinical Experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT Imaging in Prostate Cancer Patients
por: Kairemo, Kalevi, et al.
Publicado: (2014)

Radionuclide Treatment with 153Sm-EDTMP is Effective for the Palliation of Bone Pain in the Context of Extensive Bone Marrow Metastases: A Case Report
por: Kairemo, Kalevi, et al.
Publicado: (2014)

Atherosclerosis Imaging with (18)F-Sodium Fluoride PET
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2020)

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors
por: Helgebostad, Rasmus, et al.
Publicado: (2022)

Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives
por: Subbiah, Vivek, et al.
Publicado: (2017)

(64)Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors
por: Mirzaei, Siroos, et al.
Publicado: (2019)

Renal Manifestation of Birt–Hogg–Dubé Syndrome Depicted by 18F-fludeoxyglucose Positron Emission Tomography/Computed Tomography in a Patient with Hurtle Cell Thyroid Malignancy
por: Panagiotidis, Emmanouil, et al.
Publicado: (2018)

Correlation between Standardized Uptake Value of (68)Ga-DOTA-NOC Positron Emission Tomography/Computed Tomography and Pathological Classification of Neuroendocrine Tumors
por: Kaewput, Chalermrat, et al.
Publicado: (2018)

Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics
por: Kairemo, Kalevi, et al.
Publicado: (2015)

An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3′-deoxy-3′[(18)F]-Fluorothymidine Positron Emission Tomography (18)F-FLT PET/CT in Prostate Adenocarcinoma
por: Kairemo, Kalevi, et al.
Publicado: (2017)

Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine ((18)F-FLT) PET/CT in Lung Cancer
por: Kairemo, Kalevi, et al.
Publicado: (2020)

Radiomics Analysis for (177)Lu-DOTAGA-(l-y)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer—A Model Based on Clinical Example
por: Kelk, Eve, et al.
Publicado: (2021)

(18)F-FDG and (18)F-NaF PET/CT Global Assessment of Large Joint Inflammation and Bone Turnover in Rheumatoid Arthritis
por: Reddy, Natasha, et al.
Publicado: (2023)

Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of (18)F-Fluoride Metabolic Flux Than with Measurement of (18)F-Fluoride PET/CT SUV?
por: Azad, Gurdip K., et al.
Publicado: (2019)

[(18)F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Imaging in Oncology: Initial Staging and Evaluation of Cancer Therapy
por: Pauwels, Ernest K.J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_06bti3fnq0q38d0c2o3rkdj2or